Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia
- Authors
- Kim, Seok Jin; Kim, Jeeyong; Cho, Yunjung; Seo, Bo Kyoung; Kim, Byung Soo
- Issue Date
- May-2007
- Publisher
- OXFORD UNIV PRESS
- Keywords
- bortezomib; cyclophosphamide; plasma cell leukemia; multiple myeloma
- Citation
- JAPANESE JOURNAL OF CLINICAL ONCOLOGY, v.37, no.5, pp 382 - 384
- Pages
- 3
- Indexed
- SCIE
SCOPUS
- Journal Title
- JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 37
- Number
- 5
- Start Page
- 382
- End Page
- 384
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/17969
- DOI
- 10.1093/jjco/hym037
- ISSN
- 0368-2811
1465-3621
- Abstract
- Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m(2) intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 Mg/M-2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m(2) intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Radiology > 1. Journal Articles
- 2. Clinical Science > Department of Laboratory Medicine > 1. Journal Articles
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.